BAKER BROS ADVISORS LP's Q3 2021 13F: 12 new positions, 10 exits
Form 13F-HR for the quarter ended Sep 30, 2021 · filed Nov 15, 2021 · 116 reported positions · accession 0001104659-21-139109
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | Ascendis Pharma A/S (ASND) | 2.1% | 3.2% | +1.1 pts | +1M sh | +28% |
| Exited | Apellis Pharmaceuticals, Inc. (APLS) | 0.6% | — | −0.6 pts | −2.27M sh | −100% |
| Increased | Pacific Biosciences of California, Inc. (PACB) | 0.5% | 0.6% | +0.1 pts | +2.24M sh | +70% |
| Increased | Kodiak Sciences Inc. (KOD) | 5.8% | 6.2% | +0.4 pts | +543K sh | +4% |
| Increased | Travere Therapeutics, Inc. (TVTX) | 0.0% | 0.2% | +0.2 pts | +1.85M sh | +991% |
| Increased | bluebird bio, Inc. (BLUE) | 0.0% | 0.2% | +0.2 pts | +2.27M sh | +1001% |
| Increased | Legend Biotech Corporation (LEGN) | 0.3% | 0.5% | +0.2 pts | +699K sh | +42% |
| Exited | ADC Therapeutics SA (ADCT) | 0.2% | — | −0.2 pts | −1.42M sh | −100% |
| Increased | Kymera Therapeutics, Inc. (KYMR) | 0.4% | 0.6% | +0.2 pts | +426K sh | +22% |
| Reduced | Amarin Corporation plc (AMRN) | 0.5% | 0.5% | 0.0 pts | −4.6M sh | −17% |
| Exited | Protagonist Therapeutics, Inc. (PTGX) | 0.1% | — | −0.1 pts | −455K sh | −100% |
| New | DICE Therapeutics, Inc. (DICE) | — | 0.1% | +0.1 pts | +588K sh | new |
| New | Surrozen, Inc. (SRZN) | — | 0.1% | +0.1 pts | +2.5M sh | new |
| Reduced | Aurinia Pharmaceuticals Inc. (AUPH) | 0.1% | 0.1% | 0.0 pts | −599K sh | −54% |
| Increased | Centessa Pharmaceuticals plc (CNTA) | 0.0% | 0.1% | 0.0 pts | +727K sh | +182% |
| New | Tscan Therapeutics, Inc. (TCRX) | — | 0.1% | +0.1 pts | +1.43M sh | new |
| Reduced | Invitae Corporation (NVTA) | 1.5% | 1.2% | −0.3 pts | −375K sh | −4% |
| Increased | Chinook Therapeutics, Inc. (KDNY) | 0.1% | 0.1% | 0.0 pts | +823K sh | +76% |
| New | Tango Therapeutics, Inc. (TNGX) | — | 0.0% | 0.0 pts | +750K sh | new |
| Exited | IVERIC bio, Inc. (ISEE) | 0.0% | — | 0.0 pts | −1.41M sh | −100% |
| Exited | Assembly Biosciences, Inc. (ASMB) | 0.0% | — | 0.0 pts | −2.11M sh | −100% |
| Exited | Silverback Therapeutics, Inc. (SPRY) | 0.0% | — | 0.0 pts | −238K sh | −100% |
| Reduced | Novavax, Inc. (NVAX) | 0.1% | 0.1% | 0.0 pts | −35,000 sh | −24% |
| Increased | Aligos Therapeutics, Inc. (ALGS) | 0.1% | 0.1% | 0.0 pts | +466K sh | +29% |
| Exited | Chiasma, Inc. (CHMA) | 0.0% | — | 0.0 pts | −1.42M sh | −100% |
| New | Amryt Pharma plc (AMYT) | — | 0.0% | 0.0 pts | +518K sh | new |
| New | Kura Oncology, Inc. (KURA) | — | 0.0% | 0.0 pts | +304K sh | new |
| New | aTyr Pharma, Inc. (ATYR) | — | 0.0% | 0.0 pts | +625K sh | new |
| Reduced | Mereo BioPharma Group plc (MREO) | 0.0% | 0.0% | 0.0 pts | −2.17M sh | −88% |
| Exited | Orchard Therapeutics plc (ORTX) | 0.0% | — | 0.0 pts | −1.19M sh | −100% |
| New | ChemoCentryx, Inc. (CCXI) | — | 0.0% | 0.0 pts | +301K sh | new |
| Increased | MacroGenics, Inc. (MGNX) | 0.0% | 0.0% | 0.0 pts | +242K sh | +121% |
| Increased | Aerovate Therapeutics, Inc. (AVTE) | 0.1% | 0.2% | 0.0 pts | +224K sh | +16% |
| New | Vincerx Pharma, Inc. (VINC) | — | 0.0% | 0.0 pts | +241K sh | new |
| Increased | Relmada Therapeutics, Inc. (RLMD) | 0.0% | 0.0% | 0.0 pts | +124K sh | +162% |
| Increased | Biomea Fusion, Inc. (BMEA) | 0.0% | 0.0% | 0.0 pts | +231K sh | +78% |
| Increased | BioMarin Pharmaceutical Inc. (BMRN) | 2.8% | 2.6% | −0.2 pts | +31,200 sh | 0% |
| New | Sera Prognostics, Inc. (SERA) | — | 0.0% | 0.0 pts | +202K sh | new |
| New | Syndax Pharmaceuticals, Inc. (SNDX) | — | 0.0% | 0.0 pts | +111K sh | new |
| Increased | Immatics N.V. (IMTX) | 0.2% | 0.3% | 0.0 pts | +141K sh | +3% |
| Increased | Tricida, Inc. (TCDAQ) | 0.0% | 0.0% | 0.0 pts | +308K sh | +42% |
| New | Surrozen, Inc. (SRZNW) | — | 0.0% | 0.0 pts | +833K sh | new |
| Increased | Otonomy, Inc. (OTIC) | 0.1% | 0.1% | 0.0 pts | +472K sh | +7% |
| Exited | Frequency Therapeutics, Inc. (FREQ) | 0.0% | — | 0.0 pts | −55,555 sh | −100% |
| Exited | Syros Pharmaceuticals, Inc. (SYRS) | 0.0% | — | 0.0 pts | −65,497 sh | −100% |
| Increased | Cabaletta Bio, Inc. (CABA) | 0.0% | 0.0% | 0.0 pts | +25,700 sh | +4% |
| Reduced | Opthea Limited (CYVNY) | 0.1% | 0.1% | 0.0 pts | −29,265 sh | −1% |
| Increased | Incyte Corporation (INCY) | 11.9% | 9.8% | −2.2 pts | +393 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 83.4% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Seagen Inc. (SGEN) | 33.0% | 35.6% | |
| 2 | BeiGene, Ltd. (ONC) | 17.7% | 18.8% | |
| 3 | Incyte Corporation (INCY) | 11.9% | 9.8% | |
| 4 | Kodiak Sciences Inc. (KOD) | 5.8% | 6.2% | |
| 5 | Ascendis Pharma A/S (ASND) | 2.1% | 3.2% | |
| 6 | ACADIA Pharmaceuticals Inc. (ACAD) | 4.5% | 3.1% | |
| 7 | BioMarin Pharmaceutical Inc. (BMRN) | 2.8% | 2.6% | |
| 8 | argenx SE (ARGX) | 1.5% | 1.5% | |
| 9 | Prelude Therapeutics Inc. (PRLD) | 1.3% | 1.4% | |
| 10 | Invitae Corporation (NVTA) | 1.5% | 1.2% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).